3,3,7,7-Tetramethylbicyclo[3.3.1]nonan-1-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3,3,7,7-Tetramethylbicyclo[3.3.1]nonan-1-amine
• 英文别名: 3,3,7,7-tetramethylbicyclo[3.3.1]nonan-1-amine
• 化学式: C₁₃H₂₅N
• 分子量: 195.34
• InChiKey: RDBPTKRPUFZESI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE<br/>[FR] INHIBITEURS DE L'INTÉGRINE ALPHA 2 BÊTA 1 ET PROCÉDÉS D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2019178248A1

  公开（公告）日：2019-09-19

  Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.

  本文披露了抑制整合素α2β1的方法，以及使用这些方法的方法。
• METHODS OF TREATING ANTI-NMDAR-ASSOCIATED NEUROPSYCHIATRIC DISORDERS
  申请人：Vanderbilt University

  公开号：US20200368181A1

  公开（公告）日：2020-11-26

  The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.